BEGIN:VCALENDAR VERSION:2.0 PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4// BEGIN:VEVENT UID:20251006T181227EDT-4682XVsaEu@132.216.98.100 DTSTAMP:20251006T221227Z DESCRIPTION:Joignez-vous à D2R et à l’Institut du cancer Rosalind et Morris Goodman (GCI) pour un événement en l’honneur du Mois de la sensibilisatio n au cancer du sein et du Mois de l’histoire des femmes\, en collaboration avec la Fondation du cancer du sein du Québec et l’association Audace au féminin.\n\nCet événement en présentiel est ouvert à toutes et à tous. Ven ez participer à une discussion sur la manière dont l’équité\, la diversité et l’inclusion\, ainsi que les thérapies à base d’ARN guidées par la géno mique\, travaillent de concert pour faire progresser la lutte contre le ca ncer du sein. Après les mots d’ouverture de survivantes du cancer du sein\ , Jennifer Fitzpatrick et Mélissa Nelson\, l’événement proposera deux pane ls dynamiques réunissant des chercheuses et chercheurs\, des étudiantes et étudiants ainsi que des cliniciennes et cliniciens. La soirée se terminer a par une séance de réseautage autour de rafraîchissements légers.\n\nDéta ils de l'événement\n\n\n Titre: Cancer du sein et thérapies à base d’ARN : explorer des perspectives inclusives en recherche et en carrière\n Date: me rcredi 22 octobre 2025\n L'heure: de 17 h à 20 h 30\n Lieu: Cet événement en présentiel - Bellini Building Atrium\n\n\nInscription\n\nParticipez à cet te discussion transformative sur l’avenir de la lutte contre le cancer du sein. Réservez votre place avant le 19 octobre 2025 !\n\n\n Réservez votre place dès maintenant !\n\n\nAgenda\n\nVeuillez noter que les panels se dér ouleront en anglais\n\n\n \n \n 5:00PM\n Portes ouvertes\n \n \n 5:15PM\n \n Mot de bienvenue et remarques d’ouverture par :\n\n \n Giovanna Sebastiani\, Direc trice des administrations chez D2R\n Trina Johnson\, Directrice adjointe à l’Institut du cancer Rosalind et Morris Goodman (GCI)\n Jennifer Fitzpatric k\, survivante du cancer du sein et professeure adjointe\, Département de génétique humaine\, Université ɬÀï·¬\n Mélissa Nelson\, survivante du canc er du sein et responsable de programme à la Fondation cancer du sein du Qu ébec\n \n \n \n \n 5:30PM\n \n Panel avec des professeurs et des étudiants – Déco uvrez les carrières et les opportunités de recherche en thérapeutiques ARN guidées par la génomique pour lutter contre le cancer du sein de manière inclusive\n\n \n Panélistes : Alexandra Goudreau\, Yann Joly\, Alice Jason N am\, Hellen Kuasne\, Laura Palma\n Modératrice : Mariloue Daudie\n \n \n \n \n 6 :30PM\n \n Partenariat avec les patientes et la communauté – Quelles sont le s attentes et les besoins des personnes vivant avec le cancer du sein en m atière de médecine de précision? Comment peut-on améliorer l’accès aux nou velles thérapies de manière sécuritaire et efficace? \n\n \n Panélistes : El ize Dushime\, Mélissa Nelson\, Aldanie Rho\, Stephanie Wong \n Modératrice : Jennifer Fitzpatrick\n \n \n \n \n 7:30PM\n Remarques de clôture et séance de réseautage\n \n \n\n\n\n Intervenants\n\n Panel 1 | Découvrez les carrières et les opportunités de recherche en thérapeutiques ARN guidées par la génomi que pour lutter contre le cancer du sein de manière inclusive\n\n \n\n \n En savoir plus\n\n \n Alexandra Goudreau \n\n Alexandra Goudreau completed her B achelor’s in Biomedical Science and Master’s in Human Kinetics at the Univ ersity of Ottawa before beginning her PhD in Experimental Medicine at McGi ll University in 2022. Her research focuses on identifying new drug target s for treatment-resistant metastatic breast cancer. Outside the lab\, she serves on the Equity\, Diversity and Inclusion Advisory Committee at the L ady Davis Institute. She is passionate about science communication and acc essibility and about making cancer research more inclusive for both scient ists and patients.\n\n Yann Joly\n\n Yann Joly is the Director of the Centre of Genomics and Policy (CGP) at ɬÀï·¬. He is a James ɬÀï·¬ P rofessor at the Faculty of Medicine and Health Sciences\, Department of Hu man Genetics. Prof. Joly is also an associate member of the Bioethics Unit and at the Law Faculty at ɬÀï·¬. He has a secondary appointment as adjun ct professor at Yonsei University in South Korea. Prof. Joly was named adv ocatus emeritus by the Quebec Bar in 2012 and Fellow of the Canadian Acade my of Health Sciences in 2017.\n\n Alice Jisoo Nam \n\n Alice Jisoo Nam is a Ph.D. candidate in Biochemistry at ɬÀ﷬’s Rosalind & Morris Goodman Cancer Institute\, where she investigates novel mechanisms of brea st cancer progression and therapeutic resistance. One of her current proje cts focuses on the development of RNA-based therapeutics against an oncoge nic splice variant of the HER2 protein. Alice’s work bridges molecular bio logy\, bioengineering\, and clinical collaboration to advance genomics-gui ded precision medicine. Beyond the lab\, Alice is deeply committed to scie nce communication\, equity in STEM\, and trainee development.\n\n Hellen Ku asne\n\n Dr. Kuasne is a Research Associate at the Rosalind and Morris Good man Cancer Institute at ɬÀï·¬. Her work focuses on developing preclinical models for functional precision medicine applications and drug validation. In addition to her research\, Dr. Kuasne manages the Breast C ancer Biobank\, led by Dr. Park\, and serves as a site cohort coordinator for the Marathon of Hope (MoH) initiative\, coordinating genomic and trans criptomic sequencing of rare and metastatic breast cancer specimens.\n\n La ura Palma\n\n Laura received her Master of Science degree in Genetic Counse lling from the University of Toronto in 2005 and joined the Division of Me dical Genetics at the ɬÀï·¬ Health Center\, where she remains today. Laura has worked for over 20 years in the field of hereditary cance r\, counselling patients and families in both adult and pediatric settings . She is an Assistant Professor in the ɬÀï·¬ Department of Human Genetics and has contributed to the development and implementation of mainstreamin g genetic testing for breast and ovarian cancer at her hospital institutio n and is engaged in many aspects of the cancer genetics community both loc ally and nationally.\n\n Mariloue Daudier\n\n Mariloue is the Senior EDI Adv isor for the D2R initiative. She earned a Bachelor’s degree of Social Work from ɬÀï·¬ in 2013 and a Master’s degree of Social Innovation Management from HEC Montréal in 2016. She has over ten years of experienc e in EDI projects in many settings\, including the social economy sector\, community organizations\, the private and public sectors. She is regularl y invited as a speaker\, facilitator\, evaluator or trainer to share her e xpertise in EDI in different contexts.\n \n \n\n \n Panel 2 | Discover genomic -guided RNA therapeutics research careers and research opportunities to fi ght breast cancer in an inclusive way\n\n \n\n \n En savoir plus\n\n \n Elize D ushime \n\n Elize Dushime is the Health Promotion Coordinator at the Quebec Breast Cancer Foundation. With a professional training in Public Health a nd Nutrition\, she coordinates initiatives for breast cancer awareness and the promotion of healthy lifestyles.\n\n Mélissa Nelson\n\n Mélissa Nelson is a biochemist and nurse specializing in environmental health. She began her career in endocrinology research at the CHUM Research Centre before co mpleting a bachelor's degree in biochemistry and molecular medicine (genet ics option). Driven by her passion for the fight against breast cancer\, s he continued her work in Dr. Sylvie Mader’s lab at the IRIC\, focusing on molecular targeting in breast oncology. Now in remission from HER2+ hormon e-dependent breast cancer she uses her journey to raise awareness\, partic ularly among Black and racialized women\, about the importance of informat ion\, prevention\, and proactive approaches to breast cancer.\n\n Aldanie R ho\n\n Dr. Aldanie Rho is a dedicated and accomplished medical professional . She earned her medical degree in both Haiti and Canada\, graduating from Université Laval. She also holds a master's degree in public health and h as authored numerous scientific publications in psychiatry\, clinical medi cine\, and public health. Passionate about music and lifelong learning\, s he brings a well-rounded perspective to her work and community engagement. Since 2024\, she has been actively involved with Audace au Féminin\, nota bly contributing to the Campagne Têtons Ben Drôle — a breast cancer awaren ess initiative aimed at promoting screening and encouraging participation in clinical research.\n\n Stephanie Wong\n\n Stephanie Wong is an assistant professor of surgery at ɬÀï·¬ and a breast surgical oncologist at the JGH Segal Cancer Centre. A graduate of ɬÀï·¬ and the Harvard Scho ol of Public Health\, she completed a breast surgical oncology fellowship at Dana-Farber/Brigham and Women’s Cancer Centre and Massachusetts General Hospital. Dr. Wong directs the High Risk Breast Clinic at the JGH Stroll Cancer Prevention Centre and in 2021 was recipient of the FRQS Chercheurs Boursiers Cliniciens award for research on Optimizing Surgical Decision Ma king and Prevention Strategies for Women at Elevated Breast Cancer Risk.\n \n Jennifer Fitzpatrick\n\n Jennifer Fitzpatrick is a genetic counsellor and Assistant Professor in the Department of Human Genetics. She obtained her BSc in Biology from ɬÀï·¬ and her MS in Human Genetics/Geneti c Counseling from the University of Michigan. She has worked clinically at the Hospital for Sick Children\, Toronto\, the University of Maryland Med ical Center\, Baltimore\, the Montreal Children’s Hospital and the Jewish General Hospital. She is the Director of the MSc in Genetic Counselling Pr ogram and enjoys teaching and learning with students in the Faculties of M edicine\, Biomedical Sciences and Law.\n \n \n\n DTSTART:20251022T210000Z DTEND:20251023T003000Z LOCATION:CA\, Bellini Building Atrium\, 3649 Promenade Sir William Osler SUMMARY:Événement en présentiel | Cancer du sein et thérapies à base d’ARN : explorer des perspectives inclusives en recherche et en carrière URL:/dna-to-rna/fr/channels/event/evenement-en-present iel-cancer-du-sein-et-therapies-base-darn-explorer-des-perspectives-inclus ives-368005 END:VEVENT END:VCALENDAR